Emerging Markets Regulatory Tracker: China (Vol. 4 No. 33)
This article was originally published in PharmAsia News
Executive Summary
China FDA has issues its adverse drug reaction report for 2013 with coverage expanding last year to nearly 94% of the country.
You may also be interested in...
Emerging Markets Regulatory Tracker: India Plans Regulatory Overhaul
India’s health ministry has laid out basic steps towards an overhaul of drug regulation at the local level, identifying a number of areas of concern.
Emerging Markets Regulatory Tracker: China Self-Audit Results Released
China has released the results of back on proposed standards for the accreditation of clinical trial committees, investigators and sites.
Emerging Markets Regulatory Tracker: China Device Classifications
China has finalized revised rules for the classification of medical devices, which will come into effect from the start of next year.